How could emerging adjuvant and neoadjuvant immunotherapy strategies transform the treatment paradigm for genitourinary (GU) cancers?
This educational series examines the current and emerging roles of immunotherapy and antibody-drug conjugates in non-muscle-invasive and muscle-invasive bladder cancer. The series also dives into strategies for selecting and sequencing immunotherapies for patients with advanced renal cell carcinoma.
Provided by:
In Partnership with:
Current and Emerging Roles of Immunotherapy and ADCs for Patients with Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer
Current and Emerging Roles of Immunotherapy and ADCs for Patients with Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer
